Gene Delivery in Mouse Auditory Brainstem and Hindbrain Using in Utero Electroporation Laurence S David, Jamila Aitoubah, Lee Stephen Lesperance and Lu-Yang Wang*
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
REVIEW Gene Therapy
Leukemia (2001) 15, 523–544 2001 Nature Publishing Group All rights reserved 0887-6924/01 $15.00 www.nature.com/leu REVIEW Gene therapy: principles and applications to hematopoietic cells VFI Van Tendeloo1,2, C Van Broeckhoven2 and ZN Berneman1 1Laboratory of Experimental Hematology, University of Antwerp (UIA), Antwerp University Hospital (UZA), Antwerp; and 2Laboratory of Molecular Genetics, University of Antwerp (UIA), Department of Molecular Genetics, Flanders Interuniversity Institute for Biotechnology (VIB), Antwerp, Belgium Ever since the development of technology allowing the transfer Recombinant viral vectors of new genes into eukaryotic cells, the hematopoietic system has been an obvious and desirable target for gene therapy. The last 10 years have witnessed an explosion of interest in this Biological gene transfer methods make use of modified DNA approach to treat human disease, both inherited and acquired, or RNA viruses to infect the cell, thereby introducing and with the initiation of multiple clinical protocols. All gene ther- expressing its genome which contains the gene of interest (= apy strategies have two essential technical requirements. ‘transduction’).1 The most commonly used viral vectors are These are: (1) the efficient introduction of the relevant genetic discussed below. In each case, recombinant viruses have had material into the target cell and (2) the expression of the trans- gene at therapeutic levels. Conceptual and technical hurdles the genes encoding essential replicative and/or packaging pro- involved with these requirements are still the objects of active teins replaced by the gene of interest. Advantages and disad- research. To date, the most widely used and best understood vantages of each recombinant viral vector are summarized in vectors for gene transfer in hematopoietic cells are derived Table 1. -
Gene Delivery & Expression
GENE DELIVERY & EXPRESSION GENE DELIVERY & EXPRESSION LENTIVIRUS, PIGGYBAC, MINICIRCLES, AND MORE SYSTEMBIO.COM SYSTEMS FOR ANY APPLICATION: LENTIVIRAL TOOLS AND MORE In today’s busy labs, getting experiments to work right the first time is critical—not only do you want results you can trust, you want them fast. Which is why SBI has spent over a decade developing a range of exceptionally high-performing products for gene delivery and expression. From our popular high-titer lentivirus production tools to the latest in AAV-based gene delivery systems and a range of reliable integrating and non- integrating gene expression vectors, SBI delivers high-quality, cutting-edge products and services for mammalian gene delivery and expression. With products and services that have been used in thousands of peer-reviewed papers, SBI is your trusted partner for high-quality research. 04 06 12 14 PRODUCT INTEGRATING NON-INTEGRATING SERVICES SELECTOR VECTOR SYSTEMS VECTOR SYSTEMS Syn2Clone Lentiviral Enhanced Episomal Virus Packaging Vectors PiggyBac Cell Line Construction Transposon Minicircle Technology PhiC31 Integrase AAV PinPoint Targeted Integration Non-integrating Lentiviral Gene Knock-out Gene Knock-in Gene Edit AAVS1 Safe Harbor Site INDELS via NHEJ NN OR HR Donor HR Donor Vector Vector HR Donor Vector GENE INSERTION loxP loxP (with HR vector) Excision of GENE KNOCK-OUT selection cassette (with HR vector) CORRECTED GOI PRODUCT SELECTOR A WEALTH OF OPTIONS FOR GENE DELIVERY AND EXPRESSION Integrating Vectors With integrating vectors, the vector DNA becomes permanently incorporated into the genome, often at multiple copy numbers. Depending on the system, integration can be random or directed to a specific locus. -
Auditory and Vestibular Systems Objective • to Learn the Functional
Auditory and Vestibular Systems Objective • To learn the functional organization of the auditory and vestibular systems • To understand how one can use changes in auditory function following injury to localize the site of a lesion • To begin to learn the vestibular pathways, as a prelude to studying motor pathways controlling balance in a later lab. Ch 7 Key Figs: 7-1; 7-2; 7-4; 7-5 Clinical Case #2 Hearing loss and dizziness; CC4-1 Self evaluation • Be able to identify all structures listed in key terms and describe briefly their principal functions • Use neuroanatomy on the web to test your understanding ************************************************************************************** List of media F-5 Vestibular efferent connections The first order neurons of the vestibular system are bipolar cells whose cell bodies are located in the vestibular ganglion in the internal ear (NTA Fig. 7-3). The distal processes of these cells contact the receptor hair cells located within the ampulae of the semicircular canals and the utricle and saccule. The central processes of the bipolar cells constitute the vestibular portion of the vestibulocochlear (VIIIth cranial) nerve. Most of these primary vestibular afferents enter the ipsilateral brain stem inferior to the inferior cerebellar peduncle to terminate in the vestibular nuclear complex, which is located in the medulla and caudal pons. The vestibular nuclear complex (NTA Figs, 7-2, 7-3), which lies in the floor of the fourth ventricle, contains four nuclei: 1) the superior vestibular nucleus; 2) the inferior vestibular nucleus; 3) the lateral vestibular nucleus; and 4) the medial vestibular nucleus. Vestibular nuclei give rise to secondary fibers that project to the cerebellum, certain motor cranial nerve nuclei, the reticular formation, all spinal levels, and the thalamus. -
Anatomy of the Superior Olivary Complex.Pdf
Douglas Oliver University of Connecticut Health Center SUPERIOR OLIVE Auditory Pathways Auditory CORTEX GLUT Cortex GABA GLY Medial Geniculate MGB Body Inferior IC Colliculus DLL DLL COCHLEA VLL VLL DCN VCN SOC Auditory Pathways IC Organization of Superior Olivary Complex . Subdivisions and Cytoarchitecture . Neuron types . Inputs . Outputs . Synapses . Basic Circuit Cytoarchitecture of Superior Olivary Complex LSO LSO MSO MSO MNTB D MNTB M (somata & dendrites) (axons & endings) Tsuchitani, 1978, Fig. 10 Comparative anatomy of SOC Tetsufumi Ito & Shig Kuwada Binaural Basic Circuits 8 ‐ 9 Brodal Fig MSO: medial superior olive; LSO: lateral superior olive NTB: nucleus of trapezoid body; IC: inferior colliculus MSO Principle glutamate Cells . Fusiform . Bipolar . Disc‐shaped . Each dendrite innervated by a different side MSO‐In situ hybridization RPO MSO MNTB SPO LSO VGLUT1 VGLUT2 VIAAT NISSL MSO Inputs and Synapses H=high frequency EI - ILD L=low frequency EE - ITD LSO MSO L L B H B B H G LNTB TO LSO MNTB E=Excitation (glutamate) ‐‐‐ I=Inhibition (glycine) ITD CODING Unlike retinal targets, the cochlear nuclei contain maps of frequency, not location. So how does the auditory system know ‘where’ a sound is coming from? T + ITD T By comparing the interaural time differences (ITD) between the ears How is this accomplished?... LSO MSO Right Input A Right Input B C Time Code Time Code E E A A B B C C D D E E Output Output abcde Place Code abcde Place Code Excitation MSO creates a response to Left Input Left Input Inhibition interaural time differences I Time Code E Time Code DEMSO "peak" unit LSO "trough" unit ITD ITD Figure 14.2 Binaural Responses in MSO MSO Summary . -
The Superior Olivary Complex +
Excitatory and inhibitory transmission in the superior olivary complex. Ian D. Forsythe, Matt Barker, Margaret Barnes-Davies, Brian Billups, Paul Dodson, Fatima Osmani, Steven Owens and Adrian Wong. Department of Cell Physiology and Pharmacology, University of Leicester, Leicester LE1 9HN. UK. The timing and pattern of action potentials propagating into the brainstem from both cochleae contain information about the azimuth location of that sound in auditory space. This binaural information is integrated in the superior olivary complex. This part of the auditory pathway is adapted for fast conduction speeds and the preservation of timing information with several complimentary mechanisms (see Oertel, 1999; Trussell, 1999). There are large diameter axons terminating in giant somatic synapses that activate receptor ion channels with fast kinetics. The resultant postsynaptic potentials generated in the receiving neuron are integrated with a suite of voltage-gated ion channels that determine the action potential threshold, duration and repetitive firing properties. We have studied presynaptic and postsynaptic mechanisms that regulate efficacy, timing and integration of synaptic responses in the medial nucleus of the trapezoid body and the medial and lateral superior olives. Presynaptic calcium currents in the calyx of Held. The calyx of Held is a giant synaptic terminal that forms around the soma of principal cells in the Medial Nucleus of the Trapezoid Body (MNTB) (Forsythe, 1994). Each MNTB neuron receives a single calyx. Action potentials propagating into the synaptic terminal trigger the opening of P-type calcium channels (Forsythe et al. 1998) which in turn trigger the release of glutamate into the synaptic cleft (Borst et al., 1995). -
Delivery Strategies of the CRISPR-Cas9 Gene-Editing System for Therapeutic MARK Applications
Journal of Controlled Release 266 (2017) 17–26 Contents lists available at ScienceDirect Journal of Controlled Release journal homepage: www.elsevier.com/locate/jconrel Review article Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic MARK applications ⁎ Chang Liu, Li Zhang, Hao Liu, Kun Cheng Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO 64108, United States ARTICLE INFO ABSTRACT Keywords: The CRISPR-Cas9 genome-editing system is a part of the adaptive immune system in archaea and bacteria to CRISPR-Cas9 defend against invasive nucleic acids from phages and plasmids. The single guide RNA (sgRNA) of the system Delivery recognizes its target sequence in the genome, and the Cas9 nuclease of the system acts as a pair of scissors to Gene-editing cleave the double strands of DNA. Since its discovery, CRISPR-Cas9 has become the most robust platform for Gene therapy genome engineering in eukaryotic cells. Recently, the CRISPR-Cas9 system has triggered enormous interest in Non-viral delivery therapeutic applications. CRISPR-Cas9 can be applied to correct disease-causing gene mutations or engineer T Nanoparticle cells for cancer immunotherapy. The first clinical trial using the CRISPR-Cas9 technology was conducted in 2016. Despite the great promise of the CRISPR-Cas9 technology, several challenges remain to be tackled before its successful applications for human patients. The greatest challenge is the safe and efficient delivery of the CRISPR-Cas9 genome-editing system to target cells in human body. In this review, we will introduce the mo- lecular mechanism and different strategies to edit genes using the CRISPR-Cas9 system. -
Human Inheritable Genetic Modifications
Human Inheritable Genetic Modifications Assessing Scientific, Ethical, Religious, and Policy Issues Prepared by the American Association for the Advancement of Science Mark S. Frankel Audrey R. Chapman September 2000 http://www.aaas.org/spp/dspp/sfrl/germline/main.htm i This report is the product of a collaboration between the authors and a working group convened to advise the authors, and does not necessarily represent the views of American Association for the Advancement of Science or The Greenwall Foundation, which funded this study. Copyright © 2000 American Association for the Advancement of Science Cover: Designed and created by the Office of Publication Services at the American Association for the Advancement of Science. ii Table of Contents Acknowledgements…………………………………………………v Introduction………………………………………………………….1 Major Findings, Concerns, and Recommendations…………………7 Defining Inheritable Genetic Modific ation……………….………..11 Therapeutic Need…………………………………………………..13 Efficacy of Different Approaches to IGM…………………………15 Safety Issues……………………………………………………….23 Inadvertent Germ Line Modific ation………………………………26 Religious Perspectives……………………………………………..27 Ethical Analysis and Considerations……………………………….32 Ethically Appropriate Applications of IGM: Therapy versus Enhancement.………………………………………………………40 Reproductive Rights………………………………………………..44 Balancing Scientific Freedom and Responsibility…………………45 Oversight…………………………………………………………...46 Conclusion.…………………………………………………………56 Glossary…………………………………………………………….59 Appendix A: AAAS Working Group Members……………………65 -
The Inside Scoop—Evaluating Gene Delivery Methods
TECHNOLOGY FEATURE Exploiting mother nature 878 Bringing in the guns 880 BOX 1: Going the high-throughput way 876 BOX 2: Target: the endosome 878 BOX 3: RNAi craze 881 The inside scoop⎯evaluating gene delivery methods Techniques for delivering nucleic acids into mammalian cells have been around for decades. But tools and methods reagents continue to improve and target a broader range of cells and applications. Laura Bonetta reports. Pick a paper, any paper. Chances are that somewhere in the Methods section there .com/nature e is a description of a step for introducing DNA or RNA in cells. Although it has .natur w become a routine procedure, in vitro gene delivery can still be a challenge, especially when working with frail or scarce mam- http://ww malian cells. The mammalian cell membrane is oup impenetrable to large molecules that, r G like DNA, carry an electrical charge. Researchers have thus come up with an arsenal of tricks⎯from using carrier lishing molecules and viral vectors to pocking b holes in the membrane⎯to sneak nucleic Pu acids through. But no one method can be applied to all types of cells or experi- Nature ments. “You look at the articles that have 5 been published and find one that has 200 done some comparison of different trans- © fection methods for your cells. But if you HeLa cells transduced with a self-inactivating retrovirus from Clontech’s pQX (retroQ) series, don’t have any clues, you have to try dif- which expresses green fluorescent protein. (Courtesy of Clontech.) ferent reagents, to find what will work best in your hands,” says Nina Iversen, a researcher at the University of Oslo. -
Acoustically Responsive Fibers in the Vestibular Nerve of the Cat
The Journal of Neuroscience, October 1994, 74(10): 6056-6070 Acoustically Responsive Fibers in the Vestibular Nerve of the Cat Michael P. McCue1v2*a and John J. Guinan, Jr.r.2.3-4 ‘Eaton-Peabody Laboratory of Auditory Physiology, Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02114, 2Harvard-MIT Division of Health Science and Technology and Research Laboratory of Electronics, and 3Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, and 4Department of Otology and Laryngology, Harvard Medical School, Boston, Massachusetts 02115 Recordings were made from single afferent fibers in the and levels within the normal range of human hearing. We inferior vestibular nerve, which innervates the saccule and suggest a number of auditory roles that these fibers may posterior semicircular canal. A substantial portion of the fi- play in the everyday life of mammals. bers with irregular background activity increased their firing [Key words: saccule, otoliths, auditory system, mamma- in response to moderately intense clicks and tones. lian sound reception, middle-ear muscles, cochlear nucleus] In responsive fibers, acoustic clicks evoked action poten- tials with minimum latencies of I 1 .O msec. Fibers fell into The vertebrate inner ear contains several senseorgans involved two classes, with the shortest latency either to condensation in the maintenance of equilibrium and the detection of vibra- clicks (PUSH fibers) or to rarefaction clicks (PULL fibers). tion. The precise sensory role assumedby homologous organs Low-frequency (800 Hz) tone bursts at moderately high sound varies among species.For example, the sacculeis thought to act levels (>80 dB SPL) caused synchronization of spikes to asa linear accelerometerin mammals(Fernindez and Goldberg, preferred phases of the tone cycle. -
Processing in the Cochlear Nucleus
Processing in The Cochlear Nucleus Alan R. Palmer Medical Research Council Institute of Hearing Research University Park Nottingham NG7 2RD, UK The Auditory Nervous System Cortex Cortex MGB Medial Geniculate Body Excitatory GABAergic IC Inferior Colliculus Glycinergic DNLL Nuclei of the Lateral Lemniscus Lateral Lemniscus Cochlear Nucleus DCN PVCN MSO Lateral Superior Olive AVCN Medial Superior Olive Cochlea MNTB Medial Nucleus of the Trapezoid Body Superior Olive The cochlear nucleus is the site of termination of fibres of the auditory nerve Cochlear Nucleus Auditory Nerve Cochlea 1 Frequency Tonotopicity Basilar membrane Inner hair cell Auditory nerve Fibre To the brain Each auditory-nerve fibre responds only to a narrow range of frequencies Tuning curve Action potential Evans 1975 2 Palmer and Evans 1975 There are many overlapping single-fibre tuning curves in the auditory nerve Audiogram Palmer and Evans 1975 Tonotopic Organisation Lorente - 1933 3 Tonotopic Organisation Base Anterior Cochlea Characteristic Basilar Membrane Frequency Hair Cells Auditory Nerve Apex Cochlear Nucleus Spiral Ganglion Posterior Tonotopic projection of auditory-nerve fibers into the cochlear nucleus Ryugo and Parks, 2003 The cochlear nucleus: the first auditory nucleus in the CNS Best frequency Position along electrode track (mm) Evans 1975 4 stellate (DCN) Inhibitory Synapse Excitatory Synapse DAS to inferior colliculus cartwheel fusiform SUPERIOR OLIVARY giant COMPLEX INFERIOR COLLICULUS granule vertical vertical OCB AANN to CN & IC via TB golgi DORSAL -
The Auditory Nervous System
The Auditory Nervous System Cortex Processing in The Superior Olivary Complex Cortex Advantages of Two Ears MGB Medial Geniculate Body • Improved detection / increased loudness Excitatory Alan R. Palmer GABAergic IC Inferior Colliculus • Removing interference from echoes GlycinergicInteraural Level Differences • Improved detection of sounds in Medical Research Council Institute of Hearing Research DNLL Nuclei of the Lateral Lemniscus interfering backgrounds University Park LateralInteraural Lemniscus Time Differences Nottingham NG7 2RD, UK Cochlear Nucleus • Spatial localization DCN • Detection of auditory motion PVCN MSO Lateral Superior Olive AVCN Medial Superior Olive Cochlea MNTB Medial Nucleus of the Trapezoid Body Superior Olive Binaural cues for Localising Sounds in Space 20 dB time 700 μs Interaural Time Differences (ITDs) Interaural Level Differences (ILDs) Nordlund Binaural Mechanisms of Sound Localization Binaural Hearing • Interaural time (or phase) difference at low frequency are initially analysed in the MSO by coincidence detectors connected by a delay line system. Interaural level differences • Interaural level differences at high frequency are initially The ability to extract specific forms of auditory analysed in the LSO by input that is inhibitory from one information using two ears , that would not be ((ghigh freq uency) ear and excitatory from the other. possible using one ear only. 1 PARALLEL PROCESSING OF INFORMATION IN THE COCHLEAR NUCLEUS To medial superior olive: information about sound To inferior colliculus: -
An Update on the Tools for Creating Transgenic Animal Models of Human Diseases – Focus on Atherosclerosis
Brazilian Journal of Medical and Biological Research (2019) 52(5): e8108, http://dx.doi.org/10.1590/1414-431X20198108 ISSN 1414-431X Review 1/7 An update on the tools for creating transgenic animal models of human diseases – focus on atherosclerosis A.S. Volobueva2, A.N. Orekhov 1,3,4, and A.V. Deykin 1 1Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia 2Laboratory of Gene Therapy, Biocad Biotechnology Company, Strelnya, Russia 3Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Moscow, Russia 4Institute for Atherosclerosis Research, Skolkovo Innovative Center, Moscow, Russia Abstract Animal models of diseases are invaluable tools of modern medicine. More than forty years have passed since the first successful experiments and the spectrum of available models, as well as the list of methods for creating them, have expanded dramatically. The major step forward in creating specific disease models was the development of gene editing techniques, which allowed for targeted modification of the animal’s genome. In this review, we discuss the available tools for creating transgenic animal models, such as transgenesis methods, recombinases, and nucleases, including zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and CRISPR/Cas9 systems. We then focus specifically on the models of atherosclerosis, especially mouse models that greatly contributed to improving our understanding of the disease pathogenesis and we outline their characteristics and limitations. Key words: Animal models; Gene editing; Atherosclerosis Introduction Model organisms are widely used in biomedicine reliability of resulting models. Moreover, uncontrolled gene for studying the pathophysiology of human diseases and expression could affect multiple pathways in the animal developing novel therapeutic and diagnostic methods.